New radioactive therapy targets Hard-to-Treat prostate cancer

NCT ID NCT07441837

Not yet recruiting Disease control Sponsor: Ankara University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a radioactive drug called terbium-161 PSMA in 60 men with metastatic prostate cancer that has worsened after standard treatments. The drug is designed to seek out and destroy cancer cells. Participants will receive three cycles of the drug, and researchers will monitor tumor response, side effects, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Terbium-161 PSMA I&T (a radioactive drug that targets prostate cancer cells)
What this could lead to: If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to other therapies.
What could go wrong: This is a small, early-phase trial with only 60 participants. The drug may not shrink tumors or improve survival, and it can cause side effects like bone marrow suppression or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Anadolu Sağlık Merkezi

Istanbul, Turkey (Türkiye)
Ankara University Medical School Dept of Nuclear Medicine

Ankara, 06590, Turkey (Türkiye)
Bilkent City Hospital

Ankara, Turkey (Türkiye)
Memorial Sisli Hospital

Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.